Christine Marie Utter - Jan 18, 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
SVP, Finance & CAO
Signature
/s/ Avraham S. Adler, attorney-in-fact
Stock symbol
PTCT
Transactions as of
Jan 18, 2022
Transactions value $
-$502,118
Form type
4
Date filed
1/20/2022, 03:50 PM
Previous filing
Jan 11, 2022
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Sale -$62.1K -1.43K -5.13% $43.50 26.4K Jan 18, 2022 Direct F1
transaction PTCT Common Stock Options Exercise $180K +10K +37.84% $18.01 36.4K Jan 18, 2022 Direct F1
transaction PTCT Common Stock Sale -$440K -10K -27.45% $44.00 26.4K Jan 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise -$180K -10K -100% $18.01 0 Jan 18, 2022 Common Stock 10K $18.01 Direct F1, F2
holding PTCT Stock Option (Right to Buy) 4.69K Jan 18, 2022 Common Stock 4.69K $40.45 Direct F2
holding PTCT Stock Option (Right to Buy) 17.8K Jan 18, 2022 Common Stock 17.8K $51.00 Direct F2
holding PTCT Stock Option (Right to Buy) 21.3K Jan 18, 2022 Common Stock 21.3K $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 10.1K Jan 18, 2022 Common Stock 10.1K $33.02 Direct F4
holding PTCT Stock Option (Right to Buy) 23.8K Jan 18, 2022 Common Stock 23.8K $51.16 Direct F5
holding PTCT Stock Option (Right to Buy) 50.8K Jan 18, 2022 Common Stock 50.8K $66.49 Direct F6
holding PTCT Stock Option (Right to Buy) 43.5K Jan 18, 2022 Common Stock 43.5K $38.10 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2021.
F2 Currently exercisable.
F3 This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F4 This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F5 This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F6 Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% ofthe shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-monthperiod thereafter, beginning on April 6, 2022.
F7 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.